Status:

RECRUITING

Spatial Memory Training and Cognitive Function

Lead Sponsor:

Douglas Mental Health University Institute

Collaborating Sponsors:

Canadian Institutes of Health Research (CIHR)

Conditions:

Mild Cognitive Impairment

Eligibility:

All Genders

55+ years

Phase:

NA

Brief Summary

Mild cognitive impairment (MCI) is often considered a transitional stage between normal aging and dementia, particularly Alzheimer's disease (AD). Patients with MCI have subjective memory complaints c...

Detailed Description

The hippocampus (HPC) is a labile structure capable of neurogenesis and synaptic plasticity throughout the lifespan, which is thought to underlie its role in learning and memory, particularly of autob...

Eligibility Criteria

Inclusion

  • Age 55 years and above.
  • Primary language is English or French.
  • Individuals having received a diagnosis of Mild Cognitive Impairment (MCI).

Exclusion

  • Self-reported having either of the following:
  • Current post-traumatic stress disorder and/or generalized anxiety disorder; Substance use disorder; Significant heart disease (i.e., stroke occurring during 5 years prior to study assessment or cardiac disease non-stabilized with medication); Severe Depression, or a Geriatric Depression Scale (GDS) score greater than 12; Current insomnia disorder.
  • Current medications for sleep problems, or use of medications that affect sleep.
  • Use of antidepressant and anti-anxiety medication for less than 3 months prior to study entry.
  • Use of analgesics with codeine (or other opioids).
  • Use of antipsychotic medication (past or current).
  • Having undergone brain surgery or ECT.
  • Self-reported colour-blindness.
  • General anesthesia in the past year.
  • Current smoker.
  • Suspected or confirmed traumatic brain injury during the last 24 months.
  • Motion sickness or intolerant to virtual reality tasks.
  • Cholesterol or hypertension medication for less than 3 months or changes expected within the next 9 months.
  • History or presence of neurological or psychiatric disorders (other than MCI) that in the opinion of the investigator may compromise patient safety or study objectives.
  • Current severe medical conditions (e.g. untreated diabetes, cancer) that in the opinion of the investigator may compromise patient safety or study objectives.
  • For female participants, severe menopausal symptoms, including hot flashes (determined from the Greene climacteric scale - any participants scoring over 15 is excluded).
  • Use of computer games that are designed to help with memory or general cognition.
  • Presence of any medical or psychological condition that, in the opinion of the principal investigator, may compromise the study objectives.
  • Presence of contra-indications for MRI scanning.

Key Trial Info

Start Date :

June 15 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 30 2030

Estimated Enrollment :

80 Patients enrolled

Trial Details

Trial ID

NCT07002996

Start Date

June 15 2025

End Date

December 30 2030

Last Update

July 23 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Douglas Mental Health University Institute

Verdun, Quebec, Canada, H4G 3E8